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What is lymphoma and how prevalent 
is it?
What is lymphoma?
Lymphoma is a cancer of the lymphoid cells and the ‘cell of origin’ 
is typically a more mature B cell and T cell. This neoplastic entity 
comprises ~100 different tumours of the blood-forming system. In 
Table 1, common lymphoma subtypes are mentioned, and Tables 1 
and 2 give a practical overview of the approach to and treatment of 
the three major clinical groupings – the two aggressive subsets v. the 
indolent subsets of lymphoma. 
Why does lymphoma matter?
Lymphoma has a widespread disease prevalence and is consistently 
among the top 10 most common malignancies worldwide. Lymphoma 
is also among the top 10 malignancies that are cured in the long 
term.[1] Diagnostic or therapeutic nihilism inherent to certain cancer 
diagnoses is therefore completely inappropriate for lymphoma. It 
is chameleon like in its varied presentations, and also mimics and 
is overshadowed by common diseases such as tuberculosis (TB). 
Therefore, despite its lower prevalence compared with TB or HIV 
in South Africa (SA), lymphoma should be on the list of differential 
diagnoses of many commonly occurring disease presentations.
What is the incidence of lymphoma 
and its impact on society?
Lymphoma incidence in the international v. African 
context
A recent age-standardised incidence rate of all subtypes of lymphoma 
in Europe was 24.5 per 100 000.[2] Lymphoma has a 10 - 100-fold 
increased incidence in HIV-infected persons – in an academic 
complex in Johannesburg, SA, an almost 20% increase was seen in 
the proportion of HIV-positive lymphoma patients in the previous 
decade.[3,4] However, as SA is the epicentre of the HIV pandemic, 
this increase is modest, and certainly not reflected in the national 
cancer registry incidence data that are inappropriately low at ~5 per 
100 000. With the more pressing concerns of HIV and TB, as well as 
poor access to healthcare, we are failing to diagnose and report large 
numbers of patients with lymphoma.[5]
Lymphoma prognosis in the international v. African context
Because of exponentially increasing gains in treatment advances in 
developed countries, lymphoma has shown significantly improved 
outcomes in the past decade compared with earlier data, a trend 
that is expected to continue.[6] The subtype incidence and outcome 
of lymphoma vary throughout different regions of the world, but 
in sub-Saharan Africa, especially, the outcome of lymphoma is 
highly affected by local factors, such as lack of diagnostic pathways, 
concomitant HIV, presumption of TB and poor access to treatment at 
expert referral centres. Haematological malignancies are a significant 
cause of death and disability in this region; nevertheless, data on the 
presentation and outcome of lymphoma remain scarce.[7,8] In cases 
associated with HIV, outcome after lymphoma treatment is poor 
compared with that in resource-rich regions, where HIV status does 
not necessarily influence the outcome.[9]
Pathophysiology 
The best way of explaining cancer development is to start with the 
cell-of-origin pathogenesis. Blood-forming stem cells differentiate 
into a myriad of cell types, and lymphoma occurs when a specific 
cell type at various stages along lymphocyte development undergoes 
malignant dysregulation, resulting in tumour growth. The lymphoid 
malignancies are unique by the sheer magnitude of developmental 
stages and cell types that can give rise to different subtypes of 
lymphoma, as reflected in the current World Health Organization 
(WHO) classification of lymphomas.[10] 
Diagnostic pathway
Five typical clinical ‘presentation syndromes’ of 
lymphoma and typical clinical confounders
• B symptoms (consisting of a triad of unexplained temperature of 
>38°C, drenching night sweats and >10% weight loss in previous 
6 months)
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• The obvious clinical confounder is the constitutional symptoms 
of solid-organ cancers, connective tissue diseases, endocrine 
syndromes, and especially of infectious diseases such as HIV and TB.
• Significant lymphadenopathy that is non-painful, often 
symmetric, with rubber-hard consistency. Although lymphoma 
can be present in smaller nodes, the ‘index diagnostic’ lymph node 
in lymphoma is >1.5 cm and present for >3 weeks 
• In the previous article,[11] we suggest a diagnostic algorithm 
to ensure that lymphadenopathy related to TB is successfully 
differentiated from lymphoma. 
• Cytopenias, especially anaemia, resulting from bone marrow 
invasion with suppression of normal blood cell production
• The differential diagnosis can be another haematological 
myeloid malignancy such as acute myeloid leukaemia (AML) or 
myelodysplastic syndrome (MDS).
• However, the differential diagnoses of cytopenias are vast and 
span across immunological and systemic diseases.
• Lymphocytosis due to lymphoma invading the bone marrow, with 
subsequent spill of tumour cells in the blood stream
• These blood-borne or ‘leukaemic’ lymphoma cells can be easily 
typified and diagnosed as malignant. The pitfall for a missed 
diagnosis is when the differential count is not requested. 
Determination of white cell count should always include a 
differential count. By the same logic, an abnormal ‘ward Hb’ 
should always be followed by the full blood count (FBC), 
differential count and blood film.
• Tumour masses that can quietly grow in body cavities, eventually 
causing symptoms by disturbance of function. These can grow 
contiguous to lymph node sites, such as lymphoblastic lymphoma 
causing a mediastinal mass and pleural effusions, or a B-cell 
lymphoma causing obstruction along the gastrointestinal tract; 
or they can be remote to lymph node sites, such as follicular 
lymphoma presenting in the humerus or skin, or primary central 
nervous system lymphoma presenting as a brain tumour
• The only way to establish the cause of a growth or mass is to 
carefully seek a histological diagnosis. Often this is enabled by 
imaging.
• Lymphoma is the primary cause of a mediastinal mass in the 
young and remains an important differential diagnosis of lung 
cancer, even in older patients. 
• In patients with pleural effusion a diagnosis may remain elusive, 
and empirical TB treatment may be started. Although perfectly 
legitimate in a TB-endemic area, patients receiving empiric TB 
treatment should be followed up after 2 weeks, and one should 
keep in mind an alternative diagnosis, such as lymphoma.[12]
Approach to diagnosis based on clinical presentation
• Lymphadenopathy and tumour masses suspicious of lymphoma. 
Increasingly, core biopsy with a wide needle (14G) is used for 
diagnosis of tumour masses, and excision biopsy is used according to 
surgical indication. Fine-needle aspiration (FNA) cytology is never 
sufficient for lymphoma diagnosis (see previous article).[11] ‘The 
issue is to get the tissue.’ Gaining timely advice from an expert in 
lymphoma diagnosis can avoid time and life lost due to fruitless FNA 
and aimless biopsies. In patients with same-size moderately enlarged 
lymphadenopathy, the cervical area is always preferred rather than 
the axillary area and the inguinal area for diagnostic biopsies. This 
increases diagnostic yield and avoids false-negative results.
• Substantial lymphocytosis. In these cases, the diagnosis of a 
lymphoma can easily be made on flow cytometry of blood. 
Acute lymphoblastic leukaemia (ALL) can be diagnosed in 
blood and is the leukaemic counterpart of acute lymphoblastic 
lymphoma. However, in clinical practice a sustained lymphocytosis 
is most often seen with the indolent lymphomas, such as chronic 
lymphocytic leukaemia (CLL). The diagnosis becomes more urgent 
if the lymphocytosis is accompanied by signs of bone marrow 
failure, such as anaemia and thrombocytopenia. Bone marrow 
examination is carried out at the discretion of the haematologist.
Helpful non-full blood count tests when considering the 
diagnosis of lymphoma
• Elevated lactate dehydrogenase (LDH). The more advanced the 
stage and the more aggressive the lymphoma, the higher the LDH. 
LDH is not solely related to red cell destruction syndromes or 
acute liver and cardiac states and is a mandatory and useful test 
when searching for malignancy. Note that a normal LDH does not 
exclude lymphoma.
• Elevated creatinine and uric acid. A sudden increase in creatinine 
in the absence of pre-existing renal insult, and accompanied by a 
high uric acid and LDH, is suggestive of an aggressive lymphoma
• Raised erythrocyte sedimentation rate (ESR). Not specific 
enough to use as a screening test. 
• Elevated canalicular liver enzymes (alkaline phosphatase and 
gamma-glutamyl transferase). These are likewise nonspecific to 
lymphoma, but in this setting must prompt consideration of the 
liver as a site of lymphomatous infiltration. 
• Coombs positivity. Accompanied by low haptoglobin and increased 
reticulocyte count points to an associated haemolytic anaemia.
Approach to the diagnostic and staging procedures of 
lymphoma 
In some lymphoma cases, the diagnosis is straightforward and the 
patient can be referred for staging and treatment. However, many 
patients are under observation, with a possible differential diagnosis 
of lymphoma. In these cases, it is advised to consult a clinical 
haematologist or an oncologist early to guide the diagnostic biopsy 
of suspicious tissue. 
Typically, diagnostic and staging procedures include the triad of:
• Imaging, usually a computed tomography (CT) scan of the neck-
thorax-abdomen-pelvis or other affected area, but increasingly a 
nuclear study with fluorodeoxyglucose (FDG)-positron emission 
tomography (PET)/CT is employed for enhanced metabolic 
screening of a neoplasm.[13]
• Histology of a tumour mass or lymph node excision biopsy, 
including genetic and molecular techniques to enhance diagnostic 
differentiation. 
• Bone marrow examination, including cytogenetic and molecular 
tests.
These procedures are adapted to the subtype of lymphoma, e.g. 
in certain low-grade lymphomas with circulating tumour cells 
(leukaemic phase of lymphoma), flow cytometry on blood and a 
clinical evaluation may be cost-effective and sufficient for diagnosis, 
whereas an FDG-PET/CT has become preferable as baseline 
investigation for Hodgkin lymphoma and may obviate the need for a 
bone marrow examination.
Restaging investigations after chemotherapy 
Restaging investigations after chemotherapy are based on the 
following considerations:
• Is the treatment non-curative? Then a clinical evaluation may 
trump invasive tests or even imaging.
• Is the treatment curative? Evaluation of the areas of initial disease 
is mandatory to restage and confirm remission.
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Treatment and prognostic approach
Based on cell-of-origin tumour histology, lymphoma is divided into 
Hodgkin lymphoma and non-Hodgkin lymphoma:
• Hodgkin lymphoma (HL). There is a simple disease classification and a 
straightforward excellent prognosis. Classic HL has a >80% cure rate.[14] 
• Non-Hodgkin lymphoma (NHL). There are ~100 NHL subtypes 
based on cell of origin, exhibiting extremely diverse predilection 
for site and degree of disease expression. Moreover, they display 
Table 1. Three clinical lymphoma groups and approach to diagnosis
Clinical 
lymphoma 
disease 
expression
Cell-of-origin 
causing 
lymphoma
Typical 
demographics
Typical lymphoma 
subtypes 
encountered in 
clinical practice
Risk to patient if 
undiagnosed and 
untreated Diagnostic urgency
Low-grade or
indolent 
lymphoma
Mature B cells 
and less often 
mature T cells
Usually a disease 
of the elderly, 
peak incidence 
~60 years
Chronic lymphocytic 
leukaemia 
Follicular lymphoma 
Splenic lymphomas
Not all indolent 
lymphomas need 
treatment
Treatment delay 
unlikely to affect 
mortality
Less urgent to diagnose and easier 
Disease often spills into bloodstream 
(‘leukaemic’), being present in bone 
marrow, or is diagnosed on a large 
tumour mass, or occurs in large spleen
High-grade 
or aggressive 
lymphoma
Mature B cells 
and less often 
mature T cells, 
occurring at an 
intermediate 
developmental 
stage
Wide spectrum 
of occurrence 
across age groups, 
prognosis better 
in the young
Diffuse large B-cell 
lymphoma
Hodgkin lymphoma
Peripheral T-cell 
lymphoma
Undiagnosed and 
untreated patients 
have a risk of dying 
within weeks - 
months
Early diagnosis is crucial: advanced 
stage of disease diminishes cure rate and 
increases mortality
Tumour lysis syndrome is possible, 
either spontaneously or on initiation of 
treatment
Very-high-
grade or very 
aggressive 
lymphoma
Immature B 
or T blastic 
cells or Burkitt 
cells with high 
turnover rate
Wide spectrum 
of occurrence 
across age groups, 
prognosis better 
in the young
Acute lymphoblastic 
lymphoma
Burkitt lymphoma 
Plasmablastic 
lymphoma
Undiagnosed and 
untreated patients 
have a risk of dying 
within days - weeks 
Refer without delay (attention to 
hydration and renal protection) 
High lactate dehydrogenase can point to 
tumour lysis syndrome
Table 2. Three clinical lymphoma groups and approach to treatment
Clinical 
lymphoma 
disease expression
Initial treatment 
approach and 
timing of therapy
Common chemotherapy 
treatment regimens  
(+/- rituximab*)
Stem cell and biological†
treatment possibilities Expected treatment outcome
Low-grade 
or indolent 
lymphoma
Treat 
symptomatically, 
i.e. based on effects 
of disease burden
If asymptomatic, 
watch and wait
Chlorambucil
Bendamustine
CHOP
CHOEP
CVP
FC
Ibrutinib† – a bruton kinase 
inhibitor
Curative treatment with 
allogeneic stem cell transplant 
is reserved for young patients 
with a high burden of disease
Largely non-curative treatment with aim 
to reduce disease burden and restore to 
asymptomatic state, unless exceptionally, 
allogeneic stem cell transplant  
High-grade 
or aggressive 
lymphoma
Treat aggressively 
and without delay, 
even if only a small 
disease burden
First line:
CHOP 
Da-EPOCH
ABVD +/- radiotherapy
 BEACOPP and 
radiotherapy
Second line:
DHAP
ICE
GDP
IGEV
Nivolumab† and 
pembroluzimab† are 
checkpoint inhibitors
Lenalidomide† is an 
immunomodulator
In patients not achieving 
remission, or at high risk 
of relapse, autologous stem 
cell transplant, or less 
often, allogeneic stem cell 
transplant, can be curative
Intent of treatment is curative 
Predictors of prognosis include: 
Age
Disease extent
Site of disease
Raised LDH
Anaemia
Typical population survival rates for 
aggressive NHL patients are ~50% and 
>80% for HL patients 
Very-high-grade 
or 
very aggressive 
lymphoma
Treat aggressively 
and without delay, 
high likelihood 
of tumour lysis 
syndrome
Intense inpatient chemo-
therapy regimens, e.g.:
 Hyper-CVAD
CODOX-M-IVAC 
 Da-EPOCH +/- dose-
dense rituximab 
High-risk disease qualifies for 
stem cell transplant
An exciting new therapy for 
resistant disease is  
CAR-T† cells utilising 
adoptive immunotherapy 
directed at tumour cells
Intent of treatment is curative and can 
be achieved in 40 - 80% of patients, 
depending on age and growth and genetic 
characteristics of the tumour
CHOP = Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), Prednisone; CHOEP = CHOP with Etoposide; CVP = Cyclophosphamide, Oncovin (Vincristine), 
Prednisone; FC = Fludarabine, Cyclophosphamide; Da-EPOCH = Dose-adjusted-Etoposide, Prednisone, Oncovin (vincristine), Cyclophosphamide, Hydroxydaunorubicin (doxorubicin); 
ABVD = Adriamycin, Bleomycin, Vincristine, Dacarbazine; BEACOPP = Bleomycin, Etoposide, doxorubicin (Adriamycin), Cyclophosphamide, Oncovin (vincristine), Procarbazine, Prednisone; 
DHAP = Dexamethasone, High-dose Ara C (cytarabine), Platinol (cisplatin); ICE = Ifosfamide, Cisplatin, Etoposide; GDP = Gemcitabine, Dexamethasone, Platinol (cisplatin); IGEV = Ifosfamide, 
GEmcitabine, Vinorelbine, prednisone; Hyper-CVAD = Cyclophosphamide, Vincristine, doxorubicin (Adriamycin), Dexamethasone in course A, and Methotrexate and Cytarabine in course B; 
CODOX-M-IVAC = Cyclophosphamide, Oncovin (vincristine), DOXorubicin-Methotrexate-Ifosfamide, VP-16 (etoposide), Ara-C (cytarabine); CAR-T = Chimeric Antigen Receptor T-cell therapy; 
LDH = lactate dehydrogenase; NHL = non-Hodgkin lymphoma; HL = Hodgkin lymphoma.
*Rituximab forms an integral part of most B-cell lymphoma chemotherapy regimens.
†Novel biological drugs.
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vastly disparate behaviour clinically; therefore, clinically and with 
regard to treatment, it is most useful to approach lymphoma based 
on three clinical presentation patterns as set out in Table 1:[15]
• the low-grade or indolent lymphoma group
• the high-grade or aggressive lymphoma group
• the very-high-grade or very aggressive lymphoma group.
Certain characteristics upfront predict the grade of aggressiveness of 
the lymphoma. Making the correct subtype diagnosis is becoming 
increasingly important, as treatment for lymphoma is progressively 
tailored to subtype. Once the diagnostic subtype is known, treatment can 
be approached within the framework of one of the three clinical groups. 
Lymphoma is treated with classic chemotherapeutic 
agents and new targeted biological therapies
Chemotherapy treatment is typically delivered in cycles, scheduled to recur 
at 2 - 4-week intervals, sometimes augmented by radiotherapy. Common 
chemotherapy regimens used in commonly occurring lymphomas are 
listed in Table 2. Patients with high-risk or aggressive disease are initially 
hospitalised, but most treatment can be delivered on an outpatient basis. 
Chemotherapy combinations are used and, increasingly, biological therapy 
is added. The most well-known biological drug in lymphoma and the 
first drug in its class for antitumour cell antibody therapy, is rituximab, an 
anti-CD20 humanised monoclonal antibody therapy. Nevertheless, the 
backbone of most initial chemotherapy schedules for lymphoma remains 
corticosteroid therapy. Increasingly, the malignant activation pathways in 
lymphoma growth are being targeted by novel biological drugs, of which 
a few examples are given in Table 2. These ‘targeted’ drugs are novel in 
action and hold the promise of revolutionising lymphoma therapy. With 
a large number of these powerful novel agents being developed, the 
future of lymphoma treatment looks better than ever, but the basics of a 
good clinical diagnostic approach through early and efficient diagnosis, 
followed by correct treatment, remain foundational to the management of 
lymphoma to optimise outcomes.
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